Patents by Inventor Minoru Murakami

Minoru Murakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10899752
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Publication number: 20200387724
    Abstract: A driver state detection device includes at least two state detection units that include a first state detection unit and a second state detection unit that detect a state of a driver of a vehicle, in which the first state detection unit and the second state detection unit are disposed at positions between which the driver is interposed in a vehicle width direction, and the first state detection unit and the second state detection unit are disposed in front of a rear end of a driver's seat.
    Type: Application
    Filed: May 27, 2020
    Publication date: December 10, 2020
    Inventors: Masaki Maruyama, Minoru Higuchi, Shinichi Murakami, Toshihiro Hashimoto
  • Patent number: 10807987
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 20, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
  • Publication number: 20200255439
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 13, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Makoto KAMATA, Hideyuki SUGIYAMA, Minoru NAKAMURA, Masataka MURAKAMI, Shuhei IKEDA, Tomohiro OKAWA, Hidekazu TOKUHARA
  • Patent number: 10737484
    Abstract: A screen printing apparatus includes: a mask guide; a mask moving mechanism; and a squeegeeing mechanism. The mask guide is provided with a mask standby position, a printing-job performing position, and a mask shelter position in this order from a first end to a second end of the mask guide. The mask moving mechanism moves the used mask positioned at the printing-job performing position to the mask shelter position such that it is possible to pick up the used mask from the second end of the mask guide.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: August 11, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Takahiro Yamamoto, Masayuki Mantani, Minoru Murakami
  • Patent number: 10688779
    Abstract: A screen printing apparatus includes an inspection region setter and an operation stop controller. The inspection region setter sets an inspection region in an inspection plane that intersects with a moving path of a mask until the mask positioned at a printing-job performing position moves to a mask shelter position by the moving mechanism. In addition, the inspection region setter excludes a passing region of the mask from the inspection region while the mask to be positioned at the mask shelter position passes over the inspection plane from the printing-job performing position.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 23, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Takahiro Yamamoto, Minoru Murakami, Shuichi Tomeoku, Takaaki Sakaue, Takashi Katsuki
  • Patent number: 10692687
    Abstract: A low noise blanking unit corresponds to a wide range of acceleration voltages (from several times higher than related voltages to low acceleration voltages) of an electron beam. A blanking unit of the measurement and inspection device includes a blanking control circuit, in which (i) an upper and a lower blanking electrodes are arranged in the irradiation direction of an electron beam; electrodes on the reverse sides of two opposing electrodes in each of the blanking electrodes arranged in the same direction are connected with the ground, (ii) when blanking is ON, positive voltages are output to remaining electrodes of the upper blanking electrode and negative voltages are output to remaining electrodes of the lower blanking electrode, and (iii) when the blanking is OFF, the same ground reference signal is output to the remaining electrodes of the upper blanking electrode and to the remaining electrodes of the lower blanking electrode.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 23, 2020
    Assignee: HITACHI HIGH-TECHNOLOGIES CORPORATION
    Inventors: Wen Li, Shinichi Murakami, Hiroyuki Takahashi, Yuko Sasaki, Minoru Yamazaki, Hajime Kawano
  • Publication number: 20200171006
    Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
  • Patent number: 10610520
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 7, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • Patent number: 10588893
    Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: March 17, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro Murakami, Hitoshi Matsushita, Kengo Matsumoto, Minoru Okada, Yohei Yuki, Noriyuki Koyama, Naohiko Kanai
  • Patent number: 10548899
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
  • Patent number: 10542649
    Abstract: A component mounting related system is provided with a first component mounting related apparatus, a second component mounting related apparatus, an electric power source provided in the first component mounting related apparatus, a first power transmission line provided in the first component mounting related apparatus, a power transmission connector, and a second power transmission line. The electric power source supplies an electric power for actuating the first component mounting related apparatus. The first power transmission line transmits the electric power in the first component mounting related apparatus. The power transmission connector transmits the electric power transmitted by the first power transmission line to the second component mounting related apparatus. The second power transmission line transmit, in the second component mounting related apparatus, the electric power supplied from the first component mounting related apparatus through the power transmission connector.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: January 21, 2020
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventors: Masayuki Mantani, Minoru Murakami
  • Patent number: 10502555
    Abstract: A laser processing system having a measurement function. The laser processing system includes a processing head configured to irradiate an object with a laser beam in a scanning manner via an optical system for processing; an illumination-light emitting section provided in the processing head, and configured to cause illumination light to be emitted from the processing head toward the object along an optical axis of the optical system for processing; a light receiving section located in a predetermined positional relationship with the illumination-light emitting section, and configured to receive a reflection of the illumination light reflected at an irradiated point on the object; and a measurement section configured to process the reflection received by the light receiving section and obtain three-dimensional measurement data of the irradiated point.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 10, 2019
    Assignee: FANUC CORPORATION
    Inventors: Minoru Nakamura, Yoshinori Murakami, Yuuki Takahashi
  • Publication number: 20190318906
    Abstract: A low noise blanking unit corresponds to a wide range of acceleration voltages (from several times higher than related voltages to low acceleration voltages) of an electron beam. A blanking unit of the measurement and inspection device includes a blanking control circuit, in which (i) an upper and a lower blanking electrodes are arranged in the irradiation direction of an electron beam; electrodes on the reverse sides of two opposing electrodes in each of the blanking electrodes arranged in the same direction are connected with the ground, (ii) when blanking is ON, positive voltages are output to remaining electrodes of the upper blanking electrode and negative voltages are output to remaining electrodes of the lower blanking electrode, and (iii) when the blanking is OFF, the same ground reference signal is output to the remaining electrodes of the upper blanking electrode and to the remaining electrodes of the lower blanking electrode.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 17, 2019
    Applicant: HITACHI HIGH-TECHNOLOGIES CORPORATION
    Inventors: Wen LI, Shinichi MURAKAMI, Hiroyuki TAKAHASHI, Yuko SASAKI, Minoru YAMAZAKI, Hajime KAWANO
  • Publication number: 20190300536
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
  • Patent number: 10428056
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Publication number: 20190256410
    Abstract: The present invention relates to a translucent structure having a surface unevenness shape which has: an area ratio of surface flat regions in which an angle formed with a flat surface is in a range of 0° to 0.5° of in a range of 0% to 5.8%; a projection density of in a range of 0.0001/?m2 to 0.05/?m2; a projection area ratio of in a range of 5.5% to 50%; a skewness Ssk which represents the degree of non-symmetry of in a range of ?0.5 to 1.1; a load area factor Smr1 at a boundary between a projected mountain portion and a core portion of in a range of 0% to 14.5%; and an arithmetic average surface roughness Sa of in a range of 0.06 ?m to 0.143 ?m.
    Type: Application
    Filed: February 19, 2019
    Publication date: August 22, 2019
    Applicant: AGC INC.
    Inventors: Masanobu ISSHIKI, Toru Ikeda, Takaaki Murakami, Yosuke Takeda, Minoru Tamada
  • Publication number: 20190248776
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Application
    Filed: April 25, 2019
    Publication date: August 15, 2019
    Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
  • Patent number: 10323027
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 18, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 10323026
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami